Data Insights

Pembrolizumab by Merck for Transitional Cell Cancer (Urothelial Cell Cancer): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Transitional Cell Cancer (Urothelial Cell Cancer). According...

Data Insights

Pembrolizumab by Merck for Colorectal Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Data Insights

Pembrolizumab by Merck for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Muscle Invasive Bladder Cancer (MIBC). According to...

Data Insights

Pembrolizumab by Merck for Glioblastoma Multiforme (GBM): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase...

Data Insights

Pembrolizumab by Merck for Malignant Pleural Mesothelioma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Pre-Registration for Malignant Pleural Mesothelioma. According to GlobalData, Pre-Registration drugs...

Data Insights

Pembrolizumab by Merck for Mycosis Fungoides: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Mycosis Fungoides. According to GlobalData, Phase II...

Data Insights

Pembrolizumab by Merck for Sezary Syndrome: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II...

Data Insights

Pembrolizumab by Merck for Thyroid Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Thyroid Cancer. According to GlobalData, Phase II...

Data Insights

Pembrolizumab by Merck for Penile Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Penile Cancer. According to GlobalData, Phase II...

Data Insights

Pembrolizumab by Merck for Metastatic Liver Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Metastatic Liver Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Metastatic Liver Cancer

Data Insights

Pembrolizumab by Merck for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Carcinoma of Unknown Primary (Occult Primary Tumor/Cancer of Unknown Primary)

Data Insights

Pembrolizumab by Merck for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Recurrent Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Recurrent Glioblastoma Multiforme (GBM)

Data Insights

Pembrolizumab by Merck for Gliosarcoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Gliosarcoma. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Gliosarcoma

Data Insights

Pembrolizumab by Merck for Uterine Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Uterine Cancer

Data Insights

Pembrolizumab by Merck for Adrenocortical Carcinoma (Adrenal Cortex Cancer): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Adrenocortical Carcinoma (Adrenal Cortex Cancer). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Adrenocortical Carcinoma (Adrenal Cortex Cancer)

Data Insights

Pembrolizumab by Merck for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Pembrolizumab by Merck for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia): Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)....

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)

Data Insights

Pembrolizumab by Merck for Kaposi Sarcoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase I for Kaposi Sarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Kaposi Sarcoma

Data Insights

Pembrolizumab by Merck for Bladder Cancer: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Bladder Cancer

Data Insights

Pembrolizumab by Merck for Marginal Zone B-cell Lymphoma: Likelihood of Approval

Pembrolizumab is under clinical development by Merck and currently in Phase II for Marginal Zone B-cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab in Marginal Zone B-cell Lymphoma